TrialStudy on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
Trial details
- Registry ID
- NCT01222286
- Phase
- Phase 2
IPHA
Innate Pharma
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
3Trials in this database
3Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaNCT01222286 | Innate Pharma | Phase 2 | Completed | 2012-07Actual |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaNCT03902184 | Innate Pharma | Phase 2 | Completed | 2026-01-08Actual |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)NCT05742607 | Innate Pharma | Phase 2 | Recruiting | 2027-06Estimated |
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Trial details
- Registry ID
- NCT03902184
- Phase
- Phase 2
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Trial details
- Registry ID
- NCT05742607
- Phase
- Phase 2
Latest recorded trial changes
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
NCT05742607 · Innate Pharma
Primary completion date
Recorded edit− Previous value
2025-06
+ Updated value
2027-06
IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
NCT03902184 · Innate Pharma
Primary completion date
Recorded edit− Previous value
2023-10-31
+ Updated value
2026-01-08
Recruitment status
Recorded edit− Previous value
Active not recruiting
+ Updated value
Completed